Iteos Therapeutics Stock Fundamentals
| ITOS Stock | USD 10.11 0.02 0.20% |
Fundamental analysis of Iteos Therapeutics allows traders to better anticipate movements in Iteos Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Iteos Therapeutics Company Current Valuation Analysis
Iteos Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Iteos Therapeutics Current Valuation | (63.73 M) |
Most of Iteos Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Iteos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Iteos Therapeutics has a Current Valuation of (63.73 Million). This is 100.44% lower than that of the Biotechnology sector and 101.37% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.38% higher than that of the company.
Iteos Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Iteos Therapeutics's current stock value. Our valuation model uses many indicators to compare Iteos Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Iteos Therapeutics competition to find correlations between indicators driving Iteos Therapeutics's intrinsic value. More Info.Iteos Therapeutics is rated fourth overall in return on equity category among its peers. It is rated third overall in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Iteos Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Iteos Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iteos Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iteos Therapeutics could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics of similar companies.Iteos Therapeutics is currently under evaluation in current valuation category among its peers.
Iteos Fundamentals
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | (63.73 M) | ||||
| Shares Outstanding | 44.17 M | ||||
| Shares Owned By Insiders | 0.98 % | ||||
| Shares Owned By Institutions | 99.02 % | ||||
| Number Of Shares Shorted | 3.07 M | ||||
| Price To Earning | 50.50 X | ||||
| Price To Book | 0.90 X | ||||
| Price To Sales | 12.78 X | ||||
| Revenue | 35 M | ||||
| EBITDA | (159.53 M) | ||||
| Net Income | (134.41 M) | ||||
| Cash And Equivalents | 791.86 M | ||||
| Cash Per Share | 22.26 X | ||||
| Total Debt | 5.1 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.42 X | ||||
| Book Value Per Share | 12.90 X | ||||
| Cash Flow From Operations | (98.18 M) | ||||
| Short Ratio | 3.76 X | ||||
| Earnings Per Share | (4.73) X | ||||
| Target Price | 10.3 | ||||
| Number Of Employees | 173 | ||||
| Beta | 1.49 | ||||
| Market Capitalization | 446.57 M | ||||
| Total Asset | 686.98 M | ||||
| Retained Earnings | (9.78 M) | ||||
| Working Capital | 469.18 M | ||||
| Net Asset | 686.98 M |
About Iteos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iteos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Iteos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.